Sunnyvale, California, January 14, 2013 - Molecular Devices® today announces it has developed an addition to the SpectraMax® product line. The new multi-mode microplate platform will have an imaging cytometer option, adding rich cellular resolution assays and visualization to well-based intensity readings. The new system will make cytometry more accessible to a wider audience, providing researchers with cellular analysis capability without the need for investment in complex imaging systems. With the ability to inspect both bright-field and fluorescent images, it will provide insight into phenotypic changes that are important for understanding cytotoxicity, cell proliferation, and protein expression.
The imaging cytometer option will provide rapid access to vital cell-based data without the complexity that is typical of automated microscopy and flow cytometry. The enhanced SoftMax® Pro Microplate Data Acquisition and Analysis Software will provide the user interface and lend step-by-step guidance, from initial setup of image acquisitions to comprehensive data analysis.
“This new platform is exemplary of our commitment to providing a flexible instrument that is capable of performing many different types of assays,” said Chris Kier, Ph.D., Molecular Devices Director of Product Management, Bioimaging. “The new imaging cytometer option will allow researchers to collapse their workflow by keeping their cell-based research within the lab and on the same instrument when requiring both cellular resolution assays and standard plate assays.”
For a sneak peak of this exciting new platform visit booth #801 at SLAS2013
T: +44 7771 730 919
At Molecular Devices
Vice President, Global Marketing
T: +1 408 747 3514
About Molecular Devices, LLC
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics
Molecular Devices is committed to the continual development of innovative solutions for life science applications. The Company is headquartered in Silicon Valley with offices around the globe.
For more information about the complete product portfolio, visit www.moleculardevices.com